Actively Negotiating the Mind–Body Divide: How Clozapine-Treated Schizophrenia Patients Make Health for Themselves

Abstract

It is well recognised that antipsychotic treatments impact the whole body, not just the target area of the brain. For people with refractory schizophrenia on clozapine, the gold standard antipsychotic treatment in England and Australia, the separation of mental and physical regimes of health is particularly pronounced, resulting in multiple, compartmentalised treatment registers. Clinicians often focus on the mental health aspects of clozapine use, using physical indicators to determine whether treatment can continue. Our observations of 59 participants in England and Australia over 18 months revealed that patients did not observe this hierarchisation of mental treatments and physical outcomes. Patients often actively engaged in the management of their bodily symptoms, leading us to advance the figure of the active, rather than passive, patient. In our paper, we do not take the position that the facility for active management is a special one utilised only by these patients. We seek instead to draw attention to what is currently overlooked as an ordinary capacity to enact some sort of control over life, even under ostensibly confined and confining circumstances. We argue that clozapine-treated schizophrenia patients utilise the clinical dichotomy between mental and physical domains of health to rework what health means to them. This permits patients to actively manage their own phenomenological ‘life projects’ (Rapport, I am Dynamite: an Alternative Anthropology of Power, Routledge, London 2003), and forces us to reconsider the notion of clinical giveness of what health means. This making of one’s own meanings of health may be critical to the maintenance of a sense of self.

This is a preview of subscription content, log in to check access.

Notes

  1. 1.

    Despite training as medical physicians, an ongoing pressure for psychiatrists, formally known as medical ‘alienists’ treating the socially estranged and incarcerated, is to legitimise the profession in strict ‘scientific’ terms (Bhugra 2014). There is a preference for neuro-psychiatry over social-psychiatry, and pharmaceutical therapy dominates personalised therapy (Bhugra 2014).

  2. 2.

    The introduction of second-generation or ‘atypical’ antipsychotic drugs dissociated ‘anti-psychotic’ efficacy and extrapyramidal side effects (movement disorders), which otherwise marked the efficacy of first-generation ‘typical’ antipsychotics (Meltzer 2010).

  3. 3.

    20–40% of schizophrenia meet this criteria for ‘treatment-resistant schizophrenia’; when psychotic symptoms are not changed after at least two trials of different anti-psychotic medications (Lambert 2010).

  4. 4.

    First available to schizophrenia patients in Europe from 1971, in 1975 clozapine was retracted from clinical use for over ten years in response to 8 fatalities in Finland, due to clozapine induced blood count complications (agranulocytosis, with 16 cases of neutropenia) (Amsler et al. 1977). Subsequent and closely monitored trials of clozapine treatment for schizophrenia saw its’ clinical reintroduction after a more conclusive study by Kane et al. in 1988 suggested that blood and heart risks could be managed via frequent blood count monitoring.

  5. 5.

    Clozapine monitoring guidelines are distributed by, and all blood results must be recorded via, a Clozapine Patient Monitoring Service (CPMS), an online database.

  6. 6.

    All diagnoses meeting the F20 criteria of the ICD-10 classification manual (WHO 1993), and all patient participants were aged between 18 and 55 as was required for ethical clearance from the NHS Health Research Authority.

  7. 7.

    Ethics approval was granted by the Australian National University HREC (2014/420), the NHS Health Research Authority (15/WA/0151) and ACT Health HREC (ETH.9.15.166).

  8. 8.

    Voice hearing can be indicative of a variety of mental illnesses but alternatively benign if culturally appropriated; clinical interpretation depends on cultural context (see Jenkins and Barrett 2004; Laroi et al. 2014). In this clozapine-treated schizophrenia context, voice-hearing indicates a persistent symptom of schizophrenia.

  9. 9.

    A further division in clinical treatment domains is between the ‘positive’ (‘psychotic’) symptoms of schizophrenia and the ‘negative’ symptoms (pertaining to the apparent loss of emotional life), which often appear to go unresolved under antipsychotic regimes (Milev et al. 2005). Clozapine appears to alleviate negative symptoms more so than alternative anti-psychotics, however evidence of clozapine’s efficacy is largely in regards to positive symptom alleviation (Meltzer 2010). Further comments on this are beyond the scope of this paper.

  10. 10.

    In binding to dopamine receptors, clozapine is metabolized by the same catalytic enzyme induced by tobacco; smokers treated with clozapine may require twice the dose of clozapine, when compared to non-smokers, to achieve similar blood levels of clozapine—and abrupt smoking cessation may result in ‘clozapine toxicity’ (Prior and Baker 2003).

References

  1. Amsler, H.; Teerenhovi, L.; Barth, E.; Harjula, K. and Vuopio, P. 1977. Agranulocytosis in Patients Treated with Clozapine: a study of the Finnish epidemic. Acta Psychiatrica Scandinavica 56(4): 241-248.

    Article  Google Scholar 

  2. Australian Commission on Safety and Quality in Health Care (ACSQHC). 2012. National Adult Clozapine Titration Chart User Guide. ACSQHC. Sydney.

    Google Scholar 

  3. Barrett, Robert. 1988. Clinical Writing and the Documentary Construction of Schizophrenia. Culture, Medicine and Psychiatry 12: 265-299.

    Article  Google Scholar 

  4. Bhugra, Dinesh. 2014. Alientated alienists: a new hope? The Lancet Psychiatry 1(4): 257-259.

    Article  Google Scholar 

  5. Biehl, João. 2005. Vita: Life in a Zone of Social Abandonment. Berkeley: University of California Press.

    Google Scholar 

  6. Biehl, João and Locke, Peter. 2010. Delueze and the Anthropology of Becoming. Current Anthropology 51(3): 317-351.

    Article  Google Scholar 

  7. Csordas, Thomas 1994 Embodiment and Experience: the Existential Ground of Culture and Self. Cambridge University Press.

  8. Delueze, Gilles. 2006. Two regimes of madness: texts and interviews 1975-1995, Los Angeles: Semiotext(e).

    Google Scholar 

  9. De Hert, Marc, Schreurs, Vincent, Vancampfort Davey Winkel Ruud. 2009. Metabolic syndrome in people with schizophrenia: a review. World Psychiatry 8: 15–22.

    Article  Google Scholar 

  10. Dennis, Simone. 2016. Forcing Things Together that are Normally Kept Apart: public health knowledge and smoking practice. Social Analysis 60(2): 116-132.

    Article  Google Scholar 

  11. Dold, Markus and Leucht, Stefan 2014. Pharmacotherapy of treatment-resistant schizophrenia. Evidence-Based Mental Health 17 (2): 33-37. doi:10.1136/eb-2014-101813

    Article  Google Scholar 

  12. Fuchs, Thomas. 2010. Phenonmeonolgy and Psychopathology. In: D Schmicksing and S. Gallagher (eds) Handbook of Phenomenology and Cognitive Science, Springer: Dordrecht, pp. 547-573.

    Google Scholar 

  13. Fuchs, Thomas. 2015. Pathologies of Intersubjectivity in Autism and Schizophrenia. Journal of Consciousness Studies 22 (1-2): 191-214.

    Google Scholar 

  14. Heidegger, Martin 1962 [1927] Being and Time. Blackwell Publishing.

  15. Jenkins, Janis. 2004. Schizophrenia as a Paradigm Case for Understanding Fundamental Human Processes. In J. Jenkins and R. Barrett (Eds.) Schizophrenia, Culture, and Subjectivity: The Edge of Experience. Cambridge: Cambridge University Press.

    Google Scholar 

  16. Jenkins, Janis. 2010. Psychopharmaceutical Self and Imaginary in the Social Field of Pschiatric Treatment. In J. Jenkins (Ed.) Pharmaceutical Self: the global shaping of experience in an age of psychopharmacology. New Mexico: School for Advanced Research Press. Pp. 17-40.

    Google Scholar 

  17. Jenkins, Janis. 2015. Extraordinary Conditions: culture and experience in mental illness. University of California Press: California

    Google Scholar 

  18. Jenkins, Janis and Barrett, Robert. 2004. Schizophrenia, Culture, and Subjectivity: The Edge of Experience. Cambridge: Cambridge University Press.

    Google Scholar 

  19. Jenkins, Janis and Carpenter-Song, Elizabeth. 2008. Stigma Despite Recovery: Strategies for Living in the Aftermath of Psychosis. Medical Anthropology Quarterly 22(3): 381–409.

    Article  Google Scholar 

  20. Kane, John; Honigfeld, Gilbert; Singer, Jack and Meltzer, Herbert. 1998. Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Archives of General Psychiatry 45: 789-796.

    Article  Google Scholar 

  21. Kapferer, Bruce. 2003. Beyond Rationalism: Rethinking Magic, Witchcraft and Sorcery. New York: Berghahn Books.

    Google Scholar 

  22. Kleinman, Arthur. 2012. Medical Anthropology and Mental Health: Five Questions for the Next Fifty Years. In: Marcia Inhorn and Emily Wentzel (eds) Medical Anthropology at the Intersections: Histories, Activisms, and Futures, Duke University Press: Durham, pp.178-196.

    Google Scholar 

  23. Lakoff, Andrew. 2005. Pharmaceutical Reason: knowledge and value in global psychiatry. Cambridge: Cambridge University Press

    Google Scholar 

  24. Laing, Ronald. 1960. The Divided Self: An Existential Study in Sanity and Madness. Harmondsworth: Penguin.

    Google Scholar 

  25. Lambert, Timothy [Representing Members of the Australian Consensus Panel for Treatment-Refractory Schizophrenia] 2010 Targeting Treatment-Refractory Schizophrenia: a multidimensional outcomes approach to the diagnosis and management of incomplete recovery. Consensus statement 2010. [Accessed in pre-publication form from Timothy Lambert, University of Sydney]

  26. Leucht, Stefan; Cipriani, Andrea; Spineli, Loukia; Mavridis, Dimitris; Orey, Deniz; Richter, Franziska; Samara, Myrto; Barbui, Corrado; Engel, Rolf; Geddes, John; Kissling, Werner; Stapf, Marko; Lässig, Bettina; Salanti, Georgia and John Davis. 2013. Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysis. Lancet 382, 951–962. 10.1016/S0140-6736(13)60733-3.

    Article  Google Scholar 

  27. Laroi, Frank; Luhrmann, Tanya; Bell, V; Christian Jr, William; Deshpande, Smita; Fernyhough, Charles; Jenkins, Janice; and Woods, Angela. 2014. Culture and Hallucinations: Overview and Future Directions. Schizophrenia Bulletin 40 suppl 4: S213-S220.

    Article  Google Scholar 

  28. Lucas, Rodney. 2001. At home with Schizophrenia. Journal of Australian Studies 25 (67): 95-102.

    Article  Google Scholar 

  29. Lucas, Rodney. 2004. In and Out of Culture: Ethnographic Means to Interpreting Schizophrenia. In J. Jenkins and R. Barrett (Eds.) Schizophrenia, Culture, and Subjectivity: The Edge of Experience. Cambridge: Cambridge University Press. Pp. 146-163.

    Google Scholar 

  30. Meltzer, Herbet. 2010. Role of Clozapine in Treatment-Resistant Schizophrenia. Advanced Biological Psychiatry 26: 114-128.

    Article  Google Scholar 

  31. Merleau-Ponty, Maurice 1962 [1945] Phenomenology of Perception. Routledge.

  32. Milev, Peter; Ho, Beng-Choon; Arndt, Stephan, and Andreasen, Nancy. 2005. Predictive Values of Neurocognition and Negative Symptoms on Functional Outcome in Schizophrenia: a longitudinal first-episode study with 7-year follow-up. American Journal of Psychiatry 162: 495-506.

    Article  Google Scholar 

  33. Morgan, Vera; Waterreus, Anna; Jablensky, Assen; Mackinnon, Andrew; McGrath, John; Carr, Vaughan; Bush, Robert; Castle, David; Cohen, Martin; Harvey, Carol; Galletly, Cherrie; Stain, Helen, Neil, Amanda; McGorry, Patrick; Hocking, Barbara; Shah, Sonal and Saw, Suzy. 2011. People living with psychotic mental illness: report on the second Australian national survey. Canberra: Commonwealth of Australia.

    Google Scholar 

  34. Myers, Neely and Ziv, Tali. 2016. “No One Ever Even Asked Me that Before”: Autobiographical power, social defeat, and recovery among African Americans with Experiences of Psychosis. Medical Anthropology Quarterly 30(3): 395-413.

    Article  Google Scholar 

  35. Nielsen, Jimmi, Correll, Christoph; Manu, Peter and Kane, John. 2013. Termination of clozapine treatment due to medical reasons: when is it warranted and how can it be avoided? Journal of Clinical Psychiatry 74, 603–613. 10.4088/JCP.12r08064quiz613.

    Article  Google Scholar 

  36. Parnas, Josef, Sass, Louis and Zahavi, Dan. 2013. Rediscovering psychopathology: the epistemology and phenomenology of the psychiatrist object. Schizophrenia Bulletin 39: 270-277.

    Article  Google Scholar 

  37. Petryna, Adriana. 2004. Biological Citizenship: the science and politics of Chernobyl-exposed populations. Osiris, 19: 250-265 (2nd Series).

    Article  Google Scholar 

  38. Prior, Trevor and Baker, Glen. 2003. Interactions between the cytochrome P450 system and the second-generation antipsychotics. Journal of Psychiatry and Neuroscience 28: 99.

    Google Scholar 

  39. Rapport Nigel. 2003. I am Dynamite: an Alternative Anthropology of Power. Routledge, London.

    Google Scholar 

  40. Robson, Debbie and Gray Richard. 2007. Serious mental illness and physical health problems: a discussion paper. International journal of Nursing Studies 443: 457–466.

    Article  Google Scholar 

  41. Salzberg, Michael and Castle, David (ed.) 2010. Physical and Mental Health: the Interface. Australian Postgraduate Medicine, Victoria.

    Google Scholar 

  42. Sartre, Jean-Paul 1969 Being and Nothingness: an Essay on Phenomenological Ontology. Routledge.

  43. Sass, Louis. 1992. Madness and Modernism: Insanity in the Light of Modern Art, Literature, and Thought. New York: Basic Books (Harvard University Press paperback 1994).

    Google Scholar 

  44. The Royal Australian and New Zealand College of Psychiatrists (RANZCP) 2015 Keeping Body and Mind Together: Improving the physical health and life expectancy of people with serious mental illness. Available at www.ranzcp.org/strategicplan

  45. Warin, Megan. 2000. The glass cage: an ethnography of exposure in schizophrenia. Health 4(1): 115–133.

    Article  Google Scholar 

  46. World Health Organisation (WHO) 1948 Constitution of the World Health Organisation. Available from: http://www.who.int/governance/eb/who_constitution_en.pdf,

  47. World Health Organisation (WHO) 1993 The ICD-10 Classification of Mental and Behavioural Disorders. Diagnostic criteria for research.

Download references

Acknowledgements

The first author thanks her research participants and Dr Emilio Fernandez-Egea (University of Cambridge) for providing additional supervisory support.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Julia E. H. Brown.

Ethics declarations

Conflict of interest

While not directly funding this study, Ms. Brown is supported by the Australian Postgraduate Award (J.B., APA 1183a/2010). However, Ms. Brown and A/Professor Dennis declare no conflicts of interest.

Ethical standards

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

Informed consent was obtained from all individual participants included in the study.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Brown, J.E.H., Dennis, S. Actively Negotiating the Mind–Body Divide: How Clozapine-Treated Schizophrenia Patients Make Health for Themselves. Cult Med Psychiatry 41, 368–381 (2017). https://doi.org/10.1007/s11013-016-9517-4

Download citation

Keywords

  • The active patient’
  • Clozapine
  • Health
  • Schizophrenia
  • Medical ethnography